In Situ Analysis of RNAi Using Affymetrix\u27 ViewRNA System by Stanney, William Joseph
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
May 2009
In Situ Analysis of RNAi Using Affymetrix'
ViewRNA System
William Joseph Stanney
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Stanney, W. J. (2009). In Situ Analysis of RNAi Using Affymetrix' ViewRNA System. Retrieved from https://digitalcommons.wpi.edu/
mqp-all/1725
MQP-ID-DSA-0568 
 
 
IN SITU ANALYSIS OF RNAi USING 
AFFYMETRIX’ VIEWRNA SYSTEM 
 
 
A Major Qualifying Project Report 
Submitted to the Faculty of the 
WORCESTER POLYTECHNIC INSTITUTE 
in partial fulfillment of the requirements for the 
Degrees of Bachelor of Science  
in 
Biology and Biotechnology 
 
by 
 
_________________________ 
William Stanney 
 
 
April 30, 2009 
 
 
APPROVED: 
 
_________________________   _________________________ 
Joanne Kamens     David Adams, Ph.D. 
Department of Discovery Research   Biology and Biotechnology 
RXi Pharmaceuticals, Inc.    WPI Project Advisor 
Major Advisor 
 2
ABSTRACT 
 
 
RNA interference (RNAi) is a powerful mechanism for gene silencing that holds 
great promise for therapeutic applications. To design a drug, scientists must find siRNA 
sequences capable of strong mRNA silencing and effective methods to deliver the siRNA 
to target tissues. In situ hybridization techniques enable the visualization of the 
effectiveness of siRNAs. This report demonstrates the visualization of RNAi mediated 
gene silencing by using a new, highly sensitive bDNA probe-based in situ hybridization 
assay known as ViewRNA. The ViewRNA System showed in both a qualitative and 
semi-quantitative manner the reduction of SOD1 mRNA after cells were transfected with 
siRNA targeting the gene. 
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BACKGROUND 
 
Superoxide Dismutase-1, General Information 
 Superoxide Dismutase 1 (SOD1) is a cytosolic enzyme that is omnipresent 
throughout virtually all eukaryotic organisms, as well as some prokaryotic organisms. 
Human SOD1 (hSOD1) is a gene that is about 1kb long that translates into a protein that 
has a molecular weight of ~16 kDa. In its active form, the SOD1 enzyme exists as a 
homodimer. (Figure-1) (Valentine et al. 2005).  
 
Figure-1: Structure of SOD1.  (a) Each SOD1 subunit binds one 
Cu++ ion (denoted in blue) and one Zn++ ion (denoted in orange) to 
catalyze the dismutation of superoxide radicals. (b) The homodimeric 
structure of SOD1.  (Valentine et al. 2005).  
 
 
The normal function of the enzyme is to convert harmful superoxide radicals (O2-.) to less 
toxic hydrogen peroxide (H2O2), using the reactions shown in Figure-2. When the 
enzyme is in its active homodimeric form, each subunit binds a Cu++ ion and a Zn++ ion.  
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This form of SOD1 is sometimes known as Cu/Zn-SOD1, to distinguish it from the 
manganese-binding mitochondrial form (Mn-SOD1).  The copper ion drives the 
dismutation of one superoxide free radical (Figure-2a). The enzyme then takes a second 
superoxide free radical along with two hydrogen ions to form one oxygen molecule and 
one hydrogen peroxide molecule (Figure-2b) (Valentine et al. 2005). Hydrogen 
peroxide, which is still harmful to the cell, is readily converted to water and oxygen by 
catalases. 
 
(a)  Cu++ + O2-. -> Cu+ + O2 
(b)  Cu+ + O2-. + 2H+ -> Cu++ + H2O2 
 
Figure-2:  The Reactions by Which SOD1 Converts 
Superoxide Radicals to Hydrogen Peroxide. 
 
 
SOD1 has one of the highest turnover numbers of any known enzyme, which 
keeps oxidative damage from superoxide radicals to a minimum (Valentine et al. 2005). 
 
SOD1 and Amyotrophic Lateral Sclerosis 
 SOD1 is a key anti-oxidative enzyme of interest in a variety of diseases induced 
by oxidative stress, but has recently become of particular interest due to its role in 
amyotrophic lateral sclerosis (ALS), sometimes referred to as Lou Gehrig’s Disease or 
Charcot-Marie-Tooth disease (Valentine et al. 2005). ALS is a most often fatal 
neurodegenerative disease characterized by the atrophy and death of upper motor neurons 
in the brain, and lower motor neurons in the spinal cord.  ALS affects roughly 1-2 people 
in every 100,000, with a female to male incidence ratio of roughly 2:3. The median age 
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of onset is 55, and, after diagnosis, patients typically survive only another three to five 
years (Boillee et al. 2006).  
Two types of ALS exist: the familial form (fALS) and the sporadic form (sALS).  
SALS accounts for roughly 90% of all ALS cases, while fALS accounts for the 
remaining 10% (Boillee et al. 2006). Early symptoms of the disease typically include 
frequent cramping, twitching, stiffness, and muscle weakness. As the disease progresses, 
patients may lose weight and experience chronic fatigue, as well as difficulty controlling 
reflexes and maintaining coordination. Eventually, simple and vital tasks such as eating, 
speaking, moving, or even breathing become impossible under the patient’s own power. 
Most often, respiratory failure or pneumonia (the occurrence of which is drastically 
augmented by the disease) is the final cause of death (Valentine et al. 2005). Diagnosing 
the disease in patients is often difficult, since there is no known biological marker unique 
to the disease. Doctors rely on other means to diagnose and track disease progression. 
Tests such as MRIs, myelograms, neurological exams, biopsies, and electromyography 
are commonly used for neurodegenerative diseases such as ALS (Valentine et al. 2005). 
While the disease is relatively rare, there is a great deal of research being conducted to 
bring it to an end (Valentine et al. 2005; Boillee et al. 2006). 
 The SOD1 enzyme was found to be responsible for about 2% of fALS cases 
through studies conducted with patients afflicted by the disease (Boillee et al. 2006). To 
date, more than 125 mutations have been documented on the SOD1 gene, though only 
114 are related to ALS (Valentine et al. 2005). Of these 114 ALS-related mutations, all 
but 12 are missense mutations, with the remainder consisting of nonsense and deletion 
mutations. Many of these mutations reduce or eliminate enzymatic activity, but some 
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have no effect on catalytic activity at all. This suggests that there may be no relation 
between SOD1 enzymatic activity and the disease. Those mutations that do affect 
enzymatic activity could lead to ALS via a toxic gain of function. Studies have been 
conducted in animals that support this hypothesis.  For example, mice lacking SOD1 
activity entirely do not suffer from nervous atrophy or death (Valentine et al. 2005), but 
mice over expressing SOD1 go on to suffer from ALS-like symptoms (Bowling et al. 
1993).  For all that is known about fALS, the underlying molecular cause of the more 
common sporadic form of the disease (sALS) has yet to be confirmed.  However, there is 
a strong focus on fALS in the hope that learning more about it could lead to potential 
treatments for sALS. 
 In the cases of the loss of physiological function, the explanation is that mutated 
SOD1 cannot compete effectively with the damaging effects of superoxide radicals, 
leading to oxidative damage from these harmful molecules (Valentine et al. 2005; Boillee 
et al. 2006).  The gain of toxic function, however, consists of many more complex 
hypotheses that all provide models for how a mutant SOD1 can lead to ALS. The first 
hypothesis (Figure-3, diagram left side) points to a mutation affecting the active site of 
the enzyme. In these mutations, the channel leading to the active site is substantially 
larger than the wild-type enzyme’s channel, allowing larger molecules to access the Cu++ 
and amino acids that catalyze the usual reaction (Valentine et al. 2005). By allowing 
larger molecules to access the active site, the enzyme can catalyze reactions that yield 
harmful molecules. Reactions such as peroxidation, which creates the dangerous OH – ion 
responsible for unbalancing the delicate pH of the cell; tyrosine nitrosylation, which 
destroys the vital amino acid tyrosine; and reverse catalysis, in which SOD1 actually 
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creates more superoxide radicals rather than destroying them, are among the potential 
reactions that can occur from this variety of mutation. Only a select few of the 
documented SOD1 mutations, however, demonstrate these characteristics, making this 
hypothesis somewhat controversial.  
 
Figure 3:  Diagram of the Two Main Hypotheses on How Mutant SOD1 
Impairs Cellular Functions.  Mutant SOD1 may cause ALS through either 
aberrant redox chemistry (left panel) or protein toxicity (right panel). In the case of 
aberrant redox chemistry, the mutant enzyme may generate such harmful products 
as hydroxide ions and nitrosylated tyrosine, or reverse its own reaction and generate 
superoxide radicals. In protein toxicity, mutant SOD1 molecules themselves may 
aggregate, overloading chaperone and proteasome function or creating aberrant 
interactions between proteins (Pasinelli and Brown, 2006). 
 
The more widely accepted model (Figure-3, diagram right side) is that mutations 
lead to unstable versions of the SOD1 protein that can aggregate, resulting in a buildup of 
improperly-folded proteins that can interfere with cellular functions and have other 
adverse effects in unrelated pathways (Boillee et al. 2006).  More support for the protein 
 10
aggregation model is shown in the link between aggregation and disease progression. 
Mice genetically engineered to express human SOD1 with mutations known to increase 
protein aggregation have been shown to come down with more severe cases of ALS. In 
addition to the interference with proteasome and chaperone activity mentioned earlier, 
aggregates can encapsulate necessary proteins that typically float freely in the cytoplasm, 
such as heat-shock protein-70 (hsp-70) (a protein that protects the cell from stress) or 
Bcl2 (a protein that prevents a cell from undergoing apoptosis), diminishing their 
activities (Boillee et al. 2006). Additionally, SOD1 aggregates can be very harmful to 
mitochondria, usually by disrupting cristae structure and the translocator outer membrane 
complex (Higgins et al. 2003).  It is unclear whether these toxic function losses or gains 
are taking place within or outside of the mitochondrion. 
 
RNAi and its Application in Treating ALS 
 Extensive research on SOD1 and its role in the onset of ALS has led to potential 
treatments for the disease. As outlined above, mutant SOD1 may be responsible for ALS; 
however, mice genetically engineered to not express SOD1 altogether show no 
developmental abnormalities (though their ability to recover from axonal stress is 
compromised) (Reaume et al. 1996). To try to treat ALS, many researchers have turned 
to a new technology in an attempt to treat this debilitating disease. In 2005, Dr. Craig 
Mello and Dr. Andrew Fire were awarded the Nobel Prize for their discovery of “small 
interfering RNAs” (siRNAs) (Fire et al. 1998). siRNAs are usually 18-25 nucleotides 
long RNA duplexes.  They are designed to contain a sequence complementary to that of a 
target mRNA product of a target gene of interest. The siRNA is incorporated into a 
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protein complex called the RNA induced silencing complex (RISC).  Once inside, the 
antisense strand of the duplex remains in RISC and directs the protein to the target 
mRNA The antisense strand can then hybridize with the mRNA and transcript and the 
protein can cleave it (Chu and Rana 2007). A protein called Argonaute is responsible for 
the catalytic activity of the RISC (Liu et al. 2004). This makes the mRNA susceptible to 
degradation by exonucleases, thus preventing the mRNA from being translated into 
protein and silencing the gene.  
 It is important to note that most companies researching RNAi use small, synthetic 
RNAs. These siRNAs are often chemically modified to prevent degradation by 
exonucleases (Chu and Rana 2007). The mechanism for natural RNAi in the cell begins 
with long, double-stranded RNAs (dsRNAs) expressed from endogenous genes (Figure-
4). A molecule called Dicer cleaves dsRNA into smaller, double-stranded RNA 
fragments, usually with a 2nt overhang at the 3’ ends (Zamore et al. 2000; Zhang et al. 
2004; Du et al. 2008). The process then continues as above. Since RNAi is a potent, 
specific method of gene silencing, it is being developed by several companies for the 
treatment of a variety of diseases. 
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Figure 4: RNAi Silences Genes by Cleaving their mRNA.   RNAi begins with a 
double-stranded RNA duplex (diagram upper left).  Typically, companies studying RNAi 
simply inject modified duplexes that resemble Dicer products that have been modified to 
protect against exonuclease activity. The strands are unwound and loaded into the RISC, 
and the passenger (sense) strand is degraded (diagram upper right). The RISC can then 
bind to mRNAs with complementary sequences to its siRNA and Ago2 can cleave the 
mRNA (diagram lower), thus silencing a gene. 
 
By delivering siRNA to the motor neurons of patients suffering from the disease, 
mutant SOD1 expression could be silenced.  The hypothesis is that silencing will occur at 
such a level that no adverse side effects will come from the treatment, since as mentioned 
previously mice and flies survive when the SOD1 gene is not expressed. Another 
advantage of this new technology is that an siRNA can be designed to be specific, so off-
target effects can be limited by design of the molecules. 
 
ViewRNA:  A Powerful New Tool in RNAi Study 
 As RNAi research advances, so must techniques that can be used in that research. 
Commonly, RNAi treatments focus on assays that allow the quantification of RNA in a 
cell, whether it is the amount of target mRNA or the levels of delivered siRNA. However, 
there are also have many questions regarding RNAi mechanisms, so there is interest in 
methods that allow for the visualization of different components for co-localization 
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experiments, and experiments to determine exactly where a therapy is being taken up 
(such as tissue type).  Although many systems exist that allow RNA quantification within 
a cell, relatively few techniques allow scientists to visualize siRNA effectiveness.  
In 2008, Affymetrix, Inc. released a system in which RNA could be visualized in 
the cell in situ through fluorescence microscopy. The system, known as ViewRNA, was 
an extension to the same company’s QuantiGene system.  QuantiGene is a branched 
DNA (bDNA) based assay that amplifies a signal by the hybridization branching of the 
probes, allowing several label enzymes to be attached to a single probe (thus is called 
bDNA) (Player et al. 2001). A luminometer is then employed to measure the amount of 
light generated by the reaction of enzymes covalently bound to the oligonucleotide probe. 
ViewRNA built upon this concept by using the same bDNA technology to allow for the 
hybridization of a fluorophore instead of an enzyme to the mRNA of interest in situ. 
Although more complicated, the ViewRNA technique had potential to enable a better 
understanding of other mechanisms of RNA silencing. 
 Both the ViewRNA and QuantiGene systems employ branched DNA (bDNA) 
technology to amplify the signal from one mRNA molecule. Unlike in QuantiGene, 
however, which requires cells be lysed beforehand to release all of the mRNA for 
sequence-based sorting, ViewRNA allows mRNA to be analyzed in situ.  The procedure 
(diagramed in Figure-5) begins by culturing adherent cells in a 96-well plate or on a 
glass slide. The cells are transfected with an siRNA oligonucleotide, which will hopefully 
silence the mRNA of interest. The next day, the cells are fixed and the probe, which is a 
small single-stranded oligonucleotide, hybridizes with a complementary sequence on the 
target mRNA. 
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Figure 5: In situ bDNA Assays Can Show Individual Copies of RNA.   In situ bDNA assays begin by 
fixing cells to a slide (upper left). The cells are then permeabilized and the probe is hybridized to the 
mRNA target (upper center). Several pre-amplifiers are then hybridized to each probe (upper right), and 
several amplifiers are hybridized to each pre-amplifiers (lower left).  Finally, several fluorophores or label 
probes are hybridized to each amplifier (lower center). These will emit a fluorescent signal that can be seen 
under a microscope (lower right), showing individual copies of mRNA (Player et al. 2001). 
 
The pre-amplifier, amplifier, and fluorophore, known as the Label Probe, are then added, 
amplifying the signal and emitting sufficient fluorescence to be seen under a microscope 
(Player et al. 2001). Finally, the cells are counterstained with DAPI and examined.  
Under designated wavelengths of light, the fluorophores are excited, and emit a 
different wavelength of light that is visible under a microscope. The fluorophores used 
emit light in the green (FITC) and red (Texas Red) wavelengths. This is useful because it 
minimizes crosstalk between fluorophores hybridized to the target mRNA (SOD1, green) 
and the positive control mRNA (PPIB, red).  In this way, each copy of the mRNAs of 
interest appears as a speck of light under a microscope. Multiple aspects of the RNAi 
mechanism can be studied in this way, including the effectiveness of the siRNA (through 
the diminishment in fluorescence) and localization (where the siRNAs and mRNA exist 
relative to one another in the cell) (Player et al. 2001). 
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ViewRNA has great potential for helping to learn more about RNAi. The assay 
has the potential to help scientists learn where siRNAs are being taken up in the body. In 
addition, it can show qualitatively how effective the siRNA is in a different region of a 
single organ; for example, how effective it is right next to a blood vessel versus farther 
away.  In addition, it can be used in co-localization experiments with labeled siRNAs to 
show RNAi in real time providing crucial evidence for the technique. Reasons like this 
give ViewRNA great promise in the research of RNAi. 
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PROJECT PURPOSE 
 
 The goals of this project were to evaluate Affymetrix’s ViewRNA Assay to 
examine its sensitivity and robustness. This, in turn, will be used to determine whether it 
can become an effective tool in visualizing siRNA silencing through the observation and 
localization of mRNA knockdown.  Data gathered from this experiment will be used to 
optimize a protocol for use by RXi Pharmaceuticals in their research of RNAi, as well as 
play a role in deciding whether the company will invest in the protocol and utilize it in 
their research. The company hopes to use the assay in the analysis of tissue samples to 
pinpoint where siRNAs are being taken up in vivo. Currently, it is difficult to know where 
siRNAs are being taken up, and the hope is that ViewRNA will be able to solve this by 
showing where mRNA levels have been reduced. This could, in turn, lead to the 
development of an RNAi-based drug capable of treating myriad debilitating human 
diseases. 
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METHODS 
 
Cell Culture and Transfection 
HeLa cells obtained from the American Type Culture Collection (ATCC) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine 
serum and 1% penicillin/streptomycin. All cells were incubated at 37oC with 10% CO2 as 
recommended by the ATCC. Two separate 96-well plates were used, one for each assay. 
For the ViewRNA assay, cells were plated in a black plastic Nunc 96-well plate with 
transparent glass bottom coated with 0.01% poly-d-lysine at 20,000 cells per well. The 
plate was set up to perform each experimental condition in triplicate. For the QuantiGene 
2.0 assay, cells were plated in a clear plastic Falcon 96-well plate at 10,000 cells per well. 
All siRNAs were synthesized by Thermo Scientific Dharmacon RNAi Technologies or 
TriLink Biotechnologies. RNA duplexes were re-constituted in 60 mM KCl, 6 mM 
HEPES (pH 7.5), and 0.2 mM MgCl2, then stored at -20oC until needed.  
Cultured cells were reverse-transfected with 25 nM total RNA duplex containing 
5 nM, 0.5 nM, or 0.05 nM siRNA 10015 (Dharmacon) or 0.5 nM siRNA 10132 
(Dharmacon), the latter miRNA has a Cy3 fluorophore hybridized to the 5’end of the 
sense strand. 10015 consisted of  a different sequence than 10132, but both bind SOD1 
mRNA. The transfection was performed using Lipofectamine (Invitrogen) transfection 
reagent according to the manufacturer’s instructions. Transfection complexes were 
prepared by adjusting the final concentration of total duplex to 25 nM with a non-
targeting control duplex (luciferase). The transfection was performed with media 
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containing no antibiotics. Cells were then incubated under normal growth conditions for 
24 hours. 
 
ViewRNA Assay 
Following transfection, cells were rinsed three times with 1X PBS (Gibco) and 
then fixed in 4% formaldehyde for thirty minutes. Following fixation, the cells were 
rinsed three more times with PBS, then permeabilized with a 1X detergent solution 
provided as part of the ViewRNA kit.  Another three-rinse cycle with PBS was 
conducted, and the cells were then treated with a 1:16,000 dilution of Proteinase 24, also 
provided with the ViewRNA kit.  The probe, which was made by Affymetrix, was then 
hybridized. The provided probe set was diluted 1:50 in Hybridization Buffer A 
(ViewRNA) and, following another rinse cycle with PBS, added to the plate, which was 
then incubated for three hours. One set of wells was only treated with the probe set for 
SOD1, one was only be treated with the probe set for PPIB, and the last was treated with 
both. Following probe hybridization the plate was rinsed three more times with Wash 
Buffer (ViewRNA), then stored overnight in Storage Buffer (ViewRNA). The next day, 
the pre-amplifier, amplifier, and label probes were hybridized. The plate was rinsed three 
times in Wash Buffer, and the pre-amplifier solution (ViewRNA) was diluted 1:250 in 
Hybridization Buffer B (ViewRNA), added to the plate, and incubated at 40oC for one 
hour. Next, the amplifier (ViewRNA) was diluted 1:250 in Hybridization Buffer B, added 
to the plate following three rinses with Wash Buffer, and incubated at 40oC for one hour. 
Finally, the Label Probe (ViewRNA) was diluted 1:250 in Hybridization Buffer C 
(ViewRNA), added to the plate after three rinses with Wash Buffer, and incubated at 
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40oC for one hour. The nuclei of cells were then counterstained with 4', 6-diamidino-2-
phenylindole (DAPI). A 10 mg/ml solution of DAPI (Invitrogen) was diluted 1:5,000 in 
PBS, and then rinsed once with PBS before the wells were filled with PBS.  At this point 
the plate was viewed under a Leica inverted microscope. Each photo was taken with the 
same parameters (including exposure time) within each channel (2 msec for phase 
contrast, 10 msec for DAPI, 600 msec for FITC, and 9 seconds for Texas Red).  Photos 
were taken with a Leica cooled CCD camera.  
Once taken and qualitatively analyzed, a quantitative method was attempted with 
an Area Density tool in LabWorks 4.6. Each photo was converted to an 8-bit image and 
the area density was calculated. Following this, the area density of each photo was 
normalized to the number of cells present in the in the DAPI image. The percent 
expression was determined by dividing the average normalized area density of photos in 
the same category (for example, all photos of cells transfected with 5 nM siRNA 10015) 
by the average normalized area density of the untransfected cells. 
 
QuantiGene 2.0 Assay 
Following transfection, the cells were lysed with a 1X lysis mixture, which was 
part of the QuantiGene 2.0 kit, and Protease K (Invitrogen).  Lysis was performed for 
thirty minutes, and the lysate was stored at -80oC until the assay could be run. The probe 
and blocking reagent were diluted in 1X lysis mixture, and then combined with cell lysate 
in the capture plate and incubated at 55oC for eighteen hours. Following incubation, the 
plate was rinsed three times with Wash Buffer (QuantiGene). After the wash, the pre-
amplifier was diluted in Amp/Label Probe Diluent (QuantiGene) and added to the plate, 
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then incubated at 55oC for one hour. Next, excess pre-amplifier was decanted, the plate 
was rinsed three times in Wash Buffer (QuantiGene), and amplifier, also diluted in 
Amp/Label Probe Diluent (QuantiGene), was added.  The plate was then incubated for 
another hour at 55oC.  Finally, excess amplifier was decanted, the plate was rinsed three 
more times with Wash Buffer (QuantiGene), and label probe, also diluted in Amp/Label 
Probe Diluent (QuantiGene), was added.  The plate was then incubated for a final hour at 
55oC. Once the label probe had been hybridized, excess label probe was decanted, the 
plate was washed three final times, and the substrate was added. The substrate was 
allowed to act for five minutes, and then the luminescence was measured on a Wallac 
Envision luminometer. The results were normalized to cyclophilin B (PPIB) expression, 
and then the percent expression relative to the untransfected cells was determined. 
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RESULTS 
 
 The SOD1 probe was designed to fluoresce green, and PPIB was designed to 
fluoresce red. The DAPI stain was included to show the location of nuclei for cell 
counting and identification, and also to localize mRNA relative to the nucleus. A phase 
contrast photo of the cell was also taken to ensure that the cells did not display any 
unusual morphology in response to any treatments. The photos showed a strong signal for 
SOD1 mRNA in negative control cells, and a diminished SOD1 signal in cells transfected 
with either targeting siRNA (10015 or 10132) (Figure-6).  The SOD1 knock down 
appeared to be dose-dependent for siRNA 10015; its efficacy was best at higher 
concentrations of siRNA.  siRNA 10132 was as effective as 10015 at the 0.5 nM dose 
tested, indicating that the attachment of the Cy3 fluorophore did not hinder its binding to 
the SOD1 target mRNA.  SOD1 mRNA exists in roughly the same abundance in the cell 
as PPIB mRNA, however the signal for PPIB was not as strong (not shown in Figure-6), 
and although it was stronger than the background, it was not strong enough to be able to 
display the ideal punctate pattern shown with SOD1.  Thus individual mRNA copies 
were difficult to distinguish for PPIB (Appendix I). 
 With respect to Cy3 fluorescence, siRNA 10132 had a Cy3 fluorophore 
covalently attached to the 5’ end of the sense strand. The hope was that this fluorophore 
would allow for co-localization experiments to be conducted between the SOD1 mRNA 
(green) and the transfected siRNA (red). Unfortunately, no fluorescence was observed 
from this fluorophore (Appendix II).  
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Figure-6: In Situ bDNA Assays Show siRNA Efficacy.  This figure shows that the ViewRNA assay 
worked successfully and also shows that both targeting siRNAs (10015 and 10132) are effective for 
knocking down SOD1 mRNA. Efficacy of 10015 is shown to be better when higher concentrations of 
siRNA are transfected. 5 nM 10015 (top row) shows complete knockdown in all transfected cells. Only one 
cell in the field of view contains SOD1siRNA, and based on the amount it is unlikely that this cell was 
transfected. 0.5 nM siRNA (second row) shows that knockdown within the cells is no longer complete, but 
still very significant. Cells transfected with 0.05 nM 10015 (third row) show still less knockdown but 
SOD1 mRNA levels are still lower than in untransfected cells (bottom row) or cells transfected with a non-
targeting control (fifth row). 0.5 nM 10132 (fourth row) showed comparable knockdown to 0.5 nM 10015. 
These images were taken at 20X magnification. 
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 ViewRNA showed a semi-quantitative capability (Figure-7) when compared to 
QuantiGene (Figure-8). The amount of SOD1 mRNA in cells transfected with siRNA 
designed to target SOD1 mRNA was lower than the amount of SOD1 mRNA in cells 
transfected with a non-targeting control or not transfected at all. In addition, as the 
concentration of active siRNA increased, SOD1 mRNA levels decreased.  siRNA 10132 
was approximately as effective as 10015 at the single 0.5 nM dose tested.  These data 
show that the ViewRNA system provides semi-quantitative data whose trends closely 
match that of the well characterized QuantiGene system. 
 
 
Figure 7: Quantitative Calculation of mRNA Using ViewRNA. This figure shows SOD1 mRNA levels 
in the cells from Figure-6 using the ViewRNA assay.  SOD1 mRNA levels are lowest when the siRNA 
dose is highest (5 nM) and increase as the dose becomes smaller. The NTC and UTC showed expression 
levels of 100%. ViewRNA is a more qualitative method, but with special software the amount of 
fluorescence in a single image can be calculated to estimate the amount of mRNA present. 
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Figure 8: Quantitative Calculation of mRNA Silencing Using QuantiGene 2.0. This figure shows the 
results from the QuantiGene 2.0 assay. SOD1 mRNA levels are lowest at 5 nM 10015 (5% SOD1 
expression) and highest when the cell was transfected with a NTC (94%) or untransfected (100%). As the 
dose of siRNA decreases, SOD1 mRNA levels rise. As a strictly quantitative assay, QuantiGene 2.0 serves 
as the benchmark for ViewRNA quantization.  
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DISCUSSION 
 
The data from this project showed that the ViewRNA system produced results as 
expected, and could be used for detection of mRNA in situ. The system successfully 
showed a reduction in green fluorescence representing SOD1 mRNA expression from 
siRNA treatment. siRNA 10015 was shown to successfully reduce SOD1 mRNA levels 
in both the ViewRNA and QuantiGene assays, and the reduction was dose-dependent. 
siRNA 10132 showed approximately equal potency at the 0.5 nM dose tested, but the 
fluorophore to which it had been covalently attached did not show up under the 
microscope. Additionally, the fluorescence of the PPIB mRNA was very faint (Appendix 
II). Quantification experiments with the ViewRNA system conducted with the help of 
software capable of measuring area density showed this technique supports results 
obtained with the standard QuantiGene results, showing that ViewRNA is a powerful tool 
not only in the qualitative application but also in semi-quantitative manner. Overall, all 
project goals were met, the experiment was a success, and a protocol was developed for 
RXi’s use of ViewRNA in their research of RNAi. 
A big part of the assay optimization came in choosing the best type of cells to 
utilize. Initially, the choice of cell line was HEK293 cells, which are a very easy to 
transfect adherent cell line. However, the cells washed away during the fixation and 
protease treatment steps. Despite several attempts to optimize formaldehyde and protease 
concentrations, the HEK293 cells did not end up working. Instead, HeLa cells were used. 
Although a significant number of cells were still washed away in the aforementioned 
steps, HeLa cells showed much improvement in remaining adhered. Optimization tests 
 26
run at RXi, and recommendations from Affymetrix, allowed optimal conditions to be 
found at 4% formaldehyde and a 1:16,000 dilution of the Proteinase K solution that was 
included in the ViewRNA kit. For this reason, it is recommended that HeLa cells be used 
for studies that will include the ViewRNA assay as part of their research. 
As part of the experiment, an siRNA had to be tested. The choice was siRNA 
10015, which had been designed to hybridize with SOD1 mRNA. Studies conducted at 
RXi prior to this project (Salomon et al, unpublished data) showed that 10015 knocked 
down SOD1 mRNA very effectively, and thus it was chosen to demonstrate the 
sensitivity of the assay.  Not surprisingly, 10015 knocked down SOD1 mRNA to nearly 
undetectable levels at a 5 nM dose. The dose-response demonstrated that, even at lower 
concentrations, 10015 was still very effective at knocking down SOD1 mRNA.  Unlike in 
past studies, more about the mechanism behind 10015’s effectiveness was learned by 
running ViewRNA in conjunction with QuantiGene 2.0.  According to the data in 
Figure-8, the QuantiGene system shows that SOD1 expression was reduced to about 5% 
of its original expression level at the 5 nM siRNA dose.  The QuantiGene 2.0 assay 
cannot determine the pattern of SOD1 expression, but by adding ViewRNA the pattern 
can be seen. The photo for 5 nM 10015 in Figure-6 shows that only one cell in the image 
displays a detectable amount of SOD1 mRNA.  All of the other cells in the image do not 
show any detectable fluorescence, showing that 5 nM is sufficient to knock down mRNA 
to almost undetectable levels in most cells. This data shows that most of the expression 
detected in QuantiGene 2.0 may actually be due to cells that, for whatever reason, may 
not be transfected with siRNA (for example, the cell in Figure 6 appears to be dividing, 
and is showing full green fluorescence), and this combination of techniques can help 
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pinpoint ideal doses to find the best balance between effect and cost, as well as better 
understand the mechanism behind RNAi. 
 Another test that was run during this experiment was conducted with siRNA 
10132.  This siRNA also bound SOD1 mRNA, but contained a Cy3 fluorophore 
covalently attached to the 5’ end of the sense strand. The hope was that this fluorophore 
would allow direct visualization of the siRNA in situ, and the localization of the siRNA 
in relation to the SOD1 mRNA transcripts. Although no fluorescence was observed, a 
comparable experiment could still be tried in the future.  In this experiment, visualization 
was attempted immediately after the transfection incubation, and again after the 
ViewRNA protocol was completed.  In future experiments this may be able to be 
performed by attempting visualization of the Cy3 fluorescence following the Day 1 
procedure of the ViewRNA assay. At this point, the cells have been fixed and much of 
the background Cy3-hybridized RNAs removed.  This time is also before the plate has 
been exposed to ambient light during the ViewRNA protocol, especially during Day 2. 
This may have resulted in bleaching of the Cy3 fluorophore, which is why it did not 
appear when the images were taken upon completion of the assay. 
 Another issue that was encountered while running the ViewRNA assay concerned 
the ability to analyze the positive control, PPIB.  This gene, which was supposed to show 
up as red on the images, was very faint (only slightly higher than background) in all of 
the wells where it was tested (both wells where it was tested as the only probe set, and 
wells where it was tested alongside the SOD1 probe set) (Appendix II).  The reasoning 
for this lack of signal for an mRNA whose abundance approximates that of SOD1 was 
not entirely clear. One possibility for the faint signal could be the filter set that was used 
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on the microscope. The Affymetrix protocol suggested using a Rhodamine filter set 
instead of a Texas Red filter set, which was used to obtain the images in Appendix I. 
Although it is somewhat unlikely since the two filter sets work in the same emission 
range, the slight difference between the two could account for the faint image, and simply 
changing the filter set could allow for PPIB to be a strong positive control. Another 
possible reason for the faint signal could be the probe set itself. PPIB mRNA exists in the 
cell in about the same copy numbers as SOD1 mRNA, so it should exhibit the same 
signal intensity. If the probe set is failing to hybridize, however, or is not hybridizing well 
with the mRNA, the signal could be less than optimal. The simplest correction would just 
be to run the experiment with a different positive control with a stronger signal, such as 
18S rRNA. 18S exists in higher copy numbers than PPIB in the cell and is more 
commonly used as a positive control.  For this reason, it is well-characterized and this 
allows companies to design better probe sets against them. Thus, the best way to improve 
the positive control may just be to choose a different gene. 
 With the initial challenge of getting the assay working complete, there are several 
future experiments that could be run. It is known that siRNA reduces mRNA levels, but 
mRNA levels are not always indicative of expression. The final protein product is what 
will determine whether an enzymatic reaction gets performed by the gene product, and as 
such, a future experiment could be to run an assay to determine whether SOD1 protein is 
still present in the cell. This could be done in several ways. The easiest ways would be a 
Western Blot or an ELISA.  Both of these assays would detect SOD1 protein still present 
in the cells, and the ELISA has the added bonus of being able to quantitate the protein 
present. Additionally, the phenotype could be checked.  Chemicals that generate 
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superoxide free radicals, like H2O2, could be added to a population of cells transfected 
with siRNA designed to knock down SOD1 mRNA, and the ability of the cell to confront 
oxidative stress could be observed. If the protein expression levels corroborate the 
mRNA levels, scientists could not only be more certain that RNAi has the ability to 
silence genes, but also that the bDNA assay used to analyze the mRNA levels in response 
to transfections with siRNA is yielding accurate results. 
 An addition to measuring protein levels, there are several other assays that could 
be run to further back up the ViewRNA assay results. While QuantiGene is a good 
measure of ViewRNA’s capabilities, it may have many of the same issues as ViewRNA, 
since both assays employ the bDNA technology. Perhaps a better measure of ViewRNA 
(and even QuantiGene) results would be made with a comparison to a different assay, 
such as polymerase chain reaction (PCR).  PCR is one of the most commonly used assays 
in the field.  It is known to be a sensitive and accurate way to measure nucleic acid levels, 
including RNA (in which case RT-PCR or reverse-transcriptase PCR would be used). 
Another future experiment to back up the data obtained in this report might employ RT-
PCR to show that ViewRNA and QuantiGene are both excellent assays for measuring 
mRNA levels. 
 In summation, the ViewRNA assay was optimized to be able to work at RXi. By 
the end of the project, it was working consistently and yielding quality results. The 
control, PPIB, only yielded faint fluorescence and needs more work before it can be used 
in the experiment. However, the in situ assay allows counting of the cells for 
normalization purposes, so this control is not necessary. siRNA 10015 was shown to be 
more potent as its concentration increased, and at a 5 nM dose reduced SOD1 mRNA 
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expression to undetectable levels in transfected cells. 10132 was also shown to be capable 
of reducing SOD1 mRNA levels; however, the fluorophore hybridized to its 5’ end was 
not able to be visualized under the microscope. Despite the shortcomings, the primary 
goal of optimizing a protocol for the ViewRNA assay was met, making the project a 
success. 
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 Appendix I: PPIB Fluorescence
This appendix shows the fluorescence noted through the Texas Red filter set. The fluorophore emitting at 
this wavelength was conjugated to PPIB. Although some fluorescence is noted that is higher than 
background, the signal is relatively faint compared to 
punctate pattern was not observed.  
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the green filter set. Additionally, the expected 
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Appendix II: Cy3 Labeled siRNA Localization 
 
 
 
This image shows the red channel of a well that only had the green (SOD1) fluorophore hybridized. This 
was to allow for the Cy3 label on siRNA 10132 to be seen without interference from the PPIB fluorophore. 
No fluorescence was noted in any of the wells for this channel, so the Cy3 labeled siRNA was not able to 
be visualized. 
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Appendix III: Optimized ViewRNA Protocol 
I. Dilution using Filler non-targeting rxRNA 
 
1. Prepare RNAi Compounds: 
a. Active siRNA stocks at 100 uM make the following: 
i. Make 0.3 uM working dilution in RNA Buffer (1:166.666 dilution) 
• Pre-dilution of 1:10 5 ul 100uM Stock + 45 ul RNA Buffer 
• For 100uM: 3ul 10uM Pre-dilition + 97 ul RNA Buffer 
b. RNA filler (11721) stock at 100 uM: 
i. Make 0.3 uM working stock in Opti-MEM (1:33.333 dilution) 
• 6 ul 100uM Stock + 1,994 ul OptiMEM 
 
2. Preparation of Labeled diluted RNAi Compound: Prepare dilutions of RNAi 
compounds in 0.2ml PCR tubes: 
a. 5 nM Condition (dilute RNA to make 12X or 60nM active in filler RNA): 
i. Add 80 ul of diluted filler RNA to tube 
ii. Add 10 ul of Labeled working stock RNAi compound (0.3 uM) to tube 
with filler 
iii. Add 10 ul of unlabeled working stock RNAi compound (0.3 uM) to tube 
with filler 
b. 0.5 nM Condition (dilute RNA compound to 12X or to 6 nM active in filler 
RNA): 
i. Add 90 ul of diluted filler RNA to tube 
ii. Add 10 ul from 60nM RNAi active compound (5nM) to tube with filler 
c. 0.05 nM Condition (dilute RNA compound to 12X or to 0.6 nM active in filler 
RNA): 
i. Add 90 ul of diluted filler RNA to each tube 
ii. Add 10 ul from 6 nM RNAi active compound (0.5 nM) to each tube with 
filler 
 
3. Preparation of unlabeled diluted RNAi Compound: Prepare dilutions of RNAi 
compounds in 0.2 ml PCR tubes: 
a. 5 nM Condition (dilute RNA to make 12X or 60nM active in filler RNA): 
i. Add 80 ul of diluted filler RNA to tube 
ii. Add 20 ul of unlabeled working stock RNAi compound (0.3uM) to tube 
with filler 
b. 0.5 nM Condition (dilute RNA compound to 12X or to 6 nM active in filler 
RNA): 
i. Add 90 ul of diluted filler RNA to tube 
ii. Add 10 ul from 60nM RNAi active compound (5nM) to tube with filler 
c. 0.05 nM Condition (dilute RNA compound to 12X or to 0.6 nM active in filler 
RNA): 
i. Add 90 ul of diluted filler RNA to each tube 
ii. Add 10 ul from 6 nM RNAi active compound (0.5nM) to each tube with 
filler 
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4. Make Bulk amount of diluted RNAiMAX. 
a. 2,205 ul Opti-MEM + 45 ul RNAiMAX 
b. Combine RNAiMAX and Opti-MEM, mix gently. 
c. Allow to sit at room temperature for about 5 minutes. 
 
5. Complexing Plates (0.2ml PCR wells, each well contains enough for duplicates per 
dose): 
a. Add 65 ul of diluted RNAiMAX to each well. 
b. Add 65 ul of diluted RNAi compound from RNA plate to each well. 
 
6. For Filler controls (25 nM concentration): 
a. Add 100 ul of diluted RNAiMAX to appropriate wells. 
b. Add 100 ul of diluted RNA filler to each well. 
 
7. After adding RNA to each well mix by pipetting up and down 3 times, gently. 
 
8. Allow complexing to take place for at least 15 minutes.  Complexes are stable at 
room temperature. 
 
9. While complexing occurs prepare cells to make a suspension at 1x105 cells/ml.  
1x104 cells are needed for each well in 100ul. 
 
10. After 15 minutes add 20 ul of complexed RNAi to each well using a multi-channel 
pipettor to each well of 96-well tissue culture treated. 
 
11. Add 100 ul of cell suspension to make final concentration of cell per well at 1x104 
and final concentration of RNAi compound will be at appropriate dose. 
 
12. Incubate for 24 hrs at 37° C, 10% CO2. 
 
II. ViewRNA Day 1 
 
Before you begin: 
• Prepare 9 mL of 4% formaldehyde by adding 1mL 37% formaldehyde to 8 
mL 1x PBS. Vortex to mix. 
• Warm Hybridization Buffer A by placing it in the 40oC incubator 30 minutes 
prior to use. 
 
1. Cell Fixation 
a. Aspirate the cell culture media from the plate and wash the cells two times with 
200µL of 1x PBS per well. 
b. Aspirate the final 1x PBS rinse and add 60µL of 4% formaldehyde solution. 
Incubate for 30 minutes at room temperature. 
c. Aspirate the 4% formaldehyde solution and rinse the plate three times with 200 
µL of 1x PBS per well. 
 37
 
2. During the fixation incubation: 
a. Prepare 6 mL of 1x Detergent Solution by adding 4 mL of 1x PBS to 4 mL of 2x 
Detergent Solution. Invert gently to mix. 
b. Prepare Protease 24 Working Solution by adding 1µL of Protease 24 stock 
solution to 8 mL of 1x PBS. Vortex to mix. 
c. Prepare12 mL of 1x Protease 24 Stop Buffer by adding 9 mL of stock Protease 24 
Stop Buffer to 3 mL of 1x PBS. Vortex to mix. 
 
3. Permeabilization Treatment 
a. Add 60 µL of 1x Detergent Solution to each well and incubate for three minutes 
at room temperature. 
b. Aspirate the 1x Detergent Solution and rinse the plate two times with 200 µL of 
1x PBS per well. 
 
4. Protease Digestion 
a. Remove the 1x PBS from the plate and add 60 µl of Protease 24 Working 
Solution to each well. Incubate for ten minutes at room temperature. 
b. Aspirate the Protease 24 Working Solution and rinse the plate three times with 
200µL of 1x PBS per well. 
c. Add 60µl of 1x Protease 24 Stop Buffer to each well. The plate is stable in Stop 
Buffer for several hours. 
 
5. Hybridization with Target Probe Set 
a. Prepare 1x Working Hybridization Buffer A by adding 4mL of the 1x Stop Buffer 
prepared in Step 2 to 4mL warmed 2x Hybridization Buffer A. 
b. Prepare Target Probe Hybridization Solution by adding 80 µl of each target probe 
(1 and 2) to 8mL of 1x Working Hybridization Buffer A. Vortex to mix. 
c. Add 60 µL of Target Probe Hybridization Solution to each well. Pipette up and 
down twice to mix. 
d. Incubate plate at 40oC for 3 hours. 
 
6. During the Incubation: 
a. Prepare 200 mL Wash Buffer by adding 600 µL Wash Buffer Component 1 and 
1mL Wash Buffer Component 2 to 198.4 mL RNAse-free water. 
b. Prepare 1x Storage Buffer by adding 4mL of stock Storage Buffer to 4 mL of 
RNase-free water. Vortex to mix. 
 
7. Plate Wash 
a. Aspirate the Target Probe Hybridization Solution. 
b. Gently add 200 µL of Wash Buffer to each well. 
c. Aspirate the wash buffer and repeat two more times with fresh Wash Buffer. 
 
8. Plate Storage 
a. Add 60 µl of 1x Storage Buffer to each well. 
b. Store the plate at 4oC. The plate must be processed within 24 hours. 
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III. ViewRNA Day 2 
 
Before you begin: 
• Warm Pre-hyb Buffer, Hybridization Buffer B, and Hybridization Buffer C by 
placing each in the 40oC incubator for 30 minutes prior to use.  
• Maintain the Pre-hyb Buffer at 40oC during the entire assay process or the 
precipitate will form. 
• Prepare 1x Working Pre-hyb Buffer by adding 6.5 mL stock 2x Pre-hyb Buffer to 
6.5 mL RNase-free water. Vortex to mix. 
• Prepare 1x Hybridization Buffer B by adding 8 mL stock 2x Hybridization Buffer 
B to 8 mL 1x Working Pre-hyb Buffer. Vortex to mix. 
• Prepare 1x Hybridization Buffer C by adding 4 mL stock 2x Hybridization Buffer 
C to 4 mL 1x Working Pre-hyb Buffer. Vortex to mix. 
  
1. Hybridization of Pre-Amplifier 
a. Wash plate twice with 200 µl Wash Buffer per well. 
b. Prepare Pre-Amplifier Hybridization Solution by adding 80 µl of each Pre-
Amplifier (1 (SOD1) and 2(PPIB)) to 8mL of 1x Hybridization Buffer B. Vortex 
to mix. 
c. Add 60 µl of Pre-Amplifier Hybridization Solution to each well. 
d. Incubate plate at 40oC for 60 minutes. The plate is stable at room temperature for 
30 minutes before and 30 minutes after the incubation. 
 
2. Plate Wash 
a. Aspirate the Pre-Amplifier Hybridization Solution. 
b. Gently add 200 µL of Wash Buffer to each well. 
c. Aspirate the wash buffer and repeat two more times with fresh Wash Buffer. 
 
3. Hybridization of Amplifier 
a. Wash plate twice with 200 µl Wash Buffer per well. 
b. Prepare Amplifier Hybridization Solution by adding 80l of each Amplifier (1 
and 2) to 8mL of 1x Hybridization Buffer B. Vortex to mix. 
c. Add 60 µl of Amplifier Hybridization Solution to each well. 
d. Incubate plate at 40oC for 60 minutes. The plate is stable at room temperature for 
30 minutes before and 30 minutes after the incubation. 
 
4. Plate Wash 
a. Aspirate the Amplifier Hybridization Solution. 
b. Gently add 200 µL of Wash Buffer to each well. 
c. Aspirate the wash buffer and repeat two more times with fresh Wash Buffer. 
 
5. Hybridization of Label Probe 
a. Wash plate twice with 200 µl Wash Buffer per well. 
b. Prepare Label Probe Hybridization Solution by adding 80 µl of each Label Probe 
(1 and 2) to 8 mL of 1x Hybridization Buffer C. Vortex to mix. 
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c. Add 60 µl of Amplifier Hybridization Solution to each well. 
d. Incubate plate at 40oC for 60 minutes. The plate is stable at room temperature for 
30 minutes before and 30 minutes after the incubation. 
 
6. Plate Wash 
a. Aspirate the Label Probe Hybridization Solution. 
b. Gently add 200 µL of Wash Buffer to each well. 
c. Aspirate the wash buffer and repeat two more times with fresh Wash Buffer. 
d. Replace Wash Buffer with 80 µl of PBS. The plate is stable for several hours at 
this stage. 
 
7. Counterstaining of Nuclei with DAPI Solution 
a. Make DAPI Working Solution by adding 1 µL of 10 mg/mL DAPI stock solution 
to 10 mL of 1X PBS. 
b. Add 60 µl of DAPI Working Solution to each well and incubate for 1 minute. 
c. Aspirate the DAPI Working Solution and wash with 200 µl of 1x PBS. 
d. Remove 1x PBS and replace with 200 µl of fresh PBS. 
e. The plate is now ready for imaging. It may also be stored at 4oC for several days. 
The plate should be sealed using adhesive seal when stored at 4oC. 
 
8. Scan Plate Using DAPI, Alexa 488, and Alexa 546 Filters 
a. Magnification: 400-fold image magnification is typically sufficient and can be 
achieved through the combined use of 10x eyepieces and a 40x oil immersion 
fluorescence objective with numeric aperture equal to or greater than 0.75. 
b. Filters: To visualize signals, the following multi-bandpass fluorescence 
microscope filter sets are required: 
 
Nucleic Acid Fluorophore Excitation Emission Purpose 
Target RNA 1 Alexa488 495 519 For detection of 1 copy/cell.  
Target RNA 2 Alexa546 546 573 For detection of 1000 copies/cell. Use 
for mid-expression housekeeping 
gene such as B-actin. 
Nuclear DNA DAPI 358 461 For focusing and cell identification 
 
